Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Charlotte K Boughton +44 (0)1223 769066
cb2000@cam.ac.uk


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs

taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs

Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Diabetes Mellitus
Diabetes Mellitus, Type 2


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The main objective of the REACTIVATE study is to investigate whether a period of intensive insulin therapy using closed-loop technology, when combined with diet and lifestyle education, can restore beta-cell function and achieve remission of recent-onset type 2 diabetes.

This is a single-centre, open-label, randomised, parallel design study comparing up to 12 weeks of fully closed-loop insulin delivery to standard care with a glucose sensor in adults with recent-onset type 2 diabetes. The primary outcome is the number of participants achieving remission of diabetes at 52 weeks, defined as HbA1c below 48mmol/mol after 12 or more weeks off all diabetes medications.

Other key outcomes include area under the curve for C-peptide and glucose during mixed meal tolerance test, the proportion of time spent with glucose levels within and above the target glucose range and mean sensor glucose as recorded by glucose sensor at 52 weeks.

Safety evaluation comprises severe hypoglycaemic episodes, and other adverse and serious adverse events. Utility and human factors outcomes include glucose sensor and closed-loop usage, questionnaires and semi-structured interviews.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Apr 2025 Dec 2028

INTERVENTIONAL

Intervention Type : DEVICE
Intervention Description : Fully automated insulin delivery with CamAPS HX app, Libre 3 glucose sensor and Ypsopump insulin pump.

Intervention Arm Group : Fully automated insulin delivery;

Intervention Type : DEVICE
Intervention Description : Standard diabetes therapy with a Freestyle Libre 3 glucose sensor

Intervention Arm Group : Standard therapy with a glucose sensor;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Addenbrooke's Hospital NHS Foundation Trust
    Cambridge
    Cambridgeshire
    CB2 0QQ

Charlotte K Boughton +44 (0)1223 769066
cb2000@cam.ac.uk



The study is sponsored by University of Cambridge and is in collaboration with Cambridge University Hospitals NHS Foundation Trust.





We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT06844539
Last updated 27 March 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.